Sanofi opens new influenza vaccine manufacturing facility in Swiftwater, Pennsylvania

Sanofi received FDA approval for an additional influenza manufacturing facility in Swiftwater, PA, expanding production of Fluzone High-Dose Quadrivalent. The $425 million investment will create up to 200 jobs.

“Our new facility will complement our existing capacities to produce enough high-dose vaccine for all people 65 and older in as many countries as possible this flu season and beyond.”news.sanofi.us

• 1 source
• news.sanofi.usNewly licensed US manufacturing facility to increase availability of Fluzone® High-Dose Quadrivalent (influenza vaccine) - Jun 17, 2021Jun 17, 2021

Summarized from public sources; check the original articles before acting on it.